Skip to content

Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma

Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05139134
Enrollment
50
Registered
2021-12-01
Start date
2022-01-01
Completion date
2022-07-30
Last updated
2022-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Bladder Urothelial Carcinoma

Keywords

CXCL5, Urothelial Carcinoma

Brief summary

Urothelial carcinoma is common malignant tumor worldwide, it remains a challenge in the oncology field, it is an ideal for research on biomarkers that could identify tumor progression and prognosis. CXCL5 have been implicated in progression of many cancers, but their significance in urinary bladder UC remains unclear.

Detailed description

Bladder carcinoma has become a common cancer globally, Incidence rates are highest in Europe, the United States and Egypt. In Egypt, bladder carcinoma was considered the third most common tumor; Egyptian males have the highest mortality rates. UC of the urinary bladder represents about 90% of all bladder cancers. CXCL5 is a chemokine, belonging to ‗ELR+' subgroup. It plays an important role in angiogenesis and tumor migration. Numerous reports have indicated that CXCL5 plays important roles in cancer progression, including cholangiocarcinoma, prostate cancer, and gastric cancer. Studying the IHC expression of CXCL5 in UC to assess its role in tumor cell proliferation, migration and spread is needed.

Interventions

None listed

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

Patients with primary invasive and non-invasive urinary bladder urothelial carcinomas. \-

Exclusion criteria

* \- Patients received pre-operative chemotherapy or radiotherapy. * Patients with insufficient clinical data. * Specimens with extensive necrosis * Tiny specimens which are insufficient for accurate diagnosis.

Design outcomes

Primary

MeasureTime frameDescription
assess the expression of CXCL5 in urothelial carcinoma1 monthImmunohistochemical study

Countries

Egypt

Contacts

Primary ContactNagwa Ahmed, Lecturer
nagwa.sadek@med.sohag.edu.eg01017415996

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026